Anlotinib as Third-Line Treatment in Patients with Refractory Advanced Non-Small Cell Lung Cancer: a Multicentre, Randomized, Double-Blind, Placebo-Controlled, Phase Ii Trial (NCT01924195)
Titel:
Anlotinib as Third-Line Treatment in Patients with Refractory Advanced Non-Small Cell Lung Cancer: a Multicentre, Randomized, Double-Blind, Placebo-Controlled, Phase Ii Trial (NCT01924195)
Auteur:
Han, B. Li, K. Zhao, Y. Li, B. Cheng, Y. Zhou, J. Lu, Y. Shi, Y. Wang, Z. Jiang, L.